EllaOne®: A second-generation emergency contraceptive?

Journal of Family Planning and Reproductive Health Care

Volumn 35, Issue 4, 2009, Pages 217-218

  Mansour, Diana ^a  

^a New Croft Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; ELLAONE; LEVONELLE; LEVONORGESTREL; POSTCOITUS CONTRACEPTIVE AGENT; ULIPRISTAL ACETATE; UNCLASSIFIED DRUG; PREGNANE DERIVATIVE; ULIPRISNIL ACETATE;

ABDOMINAL PAIN; BINDING AFFINITY; BREAST FEEDING EDUCATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EMERGENCY CONTRACEPTION; HEADACHE; HUMAN; MENSTRUATION; MENSTRUATION DISORDER; MOOD DISORDER; NAUSEA; NOTE; OVULATION INHIBITION; PREGNANCY; SIDE EFFECT; UNITED KINGDOM; VOMITING; ARTICLE; BREAST FEEDING; DRUG EFFECT; DRUG INTERACTION; MENSTRUAL CYCLE;

BREAST FEEDING; CONTRACEPTIVES, POSTCOITAL, SYNTHETIC; DRUG INTERACTIONS; HUMANS; MENSTRUAL CYCLE; NORPREGNADIENES;

EID: 70350494666     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118909789587141     Document Type: Note

References (10)

1. Ellaone®: Summary of Product Characteristics. June 2009. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ellaone/H-1027-PI-en.pdf [Accessed 4 August 2009].
2. von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002; 360: 1803-1810.
3. Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database Syst Rev 2008; 2: CD001324.
4. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002; 188: 111-123. (Pubitemid 34242671)
5. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2006). Emergency contraception. J Fam Plann Reprod Health Care 2006; 32: 121-128. http://www.ffprhc.org.uk/admin/ uploads/449-EmergencyContraceptionCEUguidance.pdf [Accessed 4 August 2009].
6. Creinin MD, Schlaff W, Archer DF, Wan L, Frezieres R, Thomas M, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol 2006; 108: 1089-1097. (Pubitemid 44665402)
7. Fine P, Ginde S, Morfesis J, Mathé H, Gainer E. A multicenter trial of ulipristal acetate for late-intake emergency contraception. Abstract presented at the 8th Congress of the European Society of Gynecology, Rome, Italy, 10-13 September 2009.
8. Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999; 353: 721.
9. Cameron S, Glasier A, Fine P, Mathé H, Gainer E. Ulipristal acetate compared to levonorgestrel for emergency contraception within five days of unprotected intercourse: a randomized controlled trial. Abstract presented at the 8th Congress of the European Society of Gynecology, Rome, Italy, 10-13 September 2009.
10. Medicines and Healthcare products Regulatory Agency. Black Triangle Scheme. http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/ Medicines/Reportingsuspectedadversedrugreactions/ Healthcareprofessionalreporting/BlackTriangleScheme/index.htm [Accessed 4 August 2009].